UNICYCIVE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 160.96 million shares for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2023-11-14
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2023-09-30 was 0.00 shares.
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2023-06-30 was 3.96M shares.
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2023-03-31 was 157.00M shares.
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2021-12-31 was 0.00 shares.
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2021 was 4.78M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month |
|---|---|---|---|---|
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 3.96M shares derived: sum of 2 quarters · filed 2023-11-14 | 160.96M shares 10-Q · filed 2023-11-14 | |
| 2023-06-30 | 3.96M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 160.96M shares 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | 157.00M shares 10-Q · filed 2023-05-16 | |||
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 4.78M shares 10-K · filed 2022-03-31 | ||
| 2021-09-30 | 4.78M shares 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |